Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine

Haematologica

Volumn 87, Issue 7, 2002, Pages 695-700

  Montillo, Marco ^a   Cafro, Anna Maria ^a   Tedeschi, Alessandra ^a   Brando, Bruno ^a   Oreste, Pierluigi ^a   Veronese, Silvio ^a   Rossi, Valentina ^a   Cairoli, Roberto ^a   Pungolino, Ester ^a   Morra, Enrica ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Campath 1H; Chronic lymphocytic leukemia; Fludarabine

Indexed keywords

ALEMTUZUMAB; CYTARABINE; FLUDARABINE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; VIDARABINE;

ADULT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BLOOD TOXICITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; EFFECTOR CELL; FEVER; GENE TARGETING; HUMAN; IMMUNOPHENOTYPING; MALE; MINIMAL RESIDUAL DISEASE; NAUSEA; NEUTROPENIA; REMISSION; THROMBOCYTE COUNT; CLINICAL TRIAL; FEMALE; MIDDLE AGED; PHARMACOKINETICS; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME; VIDARABINE;

EID: 0036076178     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Randomized comparison of fludarabine, CAP and CHOP, in 938 previously treated stage B and C chronic lymphocytic leukemia
2. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia
3. The CAMPATH 1-H antigen (CDw52)
4. Primary structure of CD52
5. Effects of CAMPATH 1 monoclonal antibodies in patients with lymphoid malignancies: Influence of antibody isotype
6. Phase II multicenter study of human CD 52 antibody in previously treated chronic lymphocytic leukemia
7. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study
8. Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders
9. In vivo "purging" of residual disease in CLL with CAMPATH 1-H
10. Monoclonal antibody-based therapies of leukemia and lymphoma
11. Subcutaneous CAMPATH-1H in fludarabine resistant/relapsed chronic lymphocytic leukemia and prolymphocytic leukemia
12. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia
13. National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
14. Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone-marrow remission using CD5-CD19 markers and PCR study of gene rearrangements
15. Detection of monoclonality in low-grade B-cell lymphomas using the polymerase chain reaction is dependent on primer selection and lymphoma type
16. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia
17. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis
18. Treatment of lymphoid malignancies with Campath 1H associated with elevated serum levels of IL-6 and TNF-α
19. Subcutaneous administration of CAMPATH 1H: Clinical and biological outcomes
20. Immunosuppressive toxicity of CAMPATH 1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma
21. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: A phase II multicenter study
22. Frequency of Cytomegalovirus Pneumonia following alemtuzumab (Campath) in Lymphoyd malignancies: Review of 1538 patients